Stephanie van Hoppe

164 Chapter 6 H. Takane, K. Kawamoto, T. Sasaki, K. Moriki, K. Moriki, H. Kitano, S. Higuchi, K. Otsubo and I. Ieiri, Life- threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan- based chemotherapy, Cancer Chemother Pharmacol 63 (2009), pp. 1165-1169. S.C. Tang, J.J. Hendrikx, J.H. Beijnen and A.H. Schinkel, Genetically modified mouse models for oral drug absorption and disposition, Curr Opin Pharmacol 13 (2013), pp. 853-858. S.C. Tang, A. Kort, K.L. Cheung, H. Rosing, T. Fukami, S. Durmus, E. Wagenaar, J.J. Hendrikx, M. Nakajima, B.J. van Vlijmen, J.H. Beijnen and A.H. Schinkel, P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice, Mol Pharm 12 (2015), pp. 3714-3723. S.C. Tang, R.W. Sparidans, K.L. Cheung, T. Fukami, S. Durmus, E. Wagenaar, T. Yokoi, B.J. van Vlijmen, J.H. Beijnen and A.H. Schinkel, P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice, Clin Cancer Res 20 (2014), pp. 3133-3145. N. Thakkar, A.C. Lockhart and W. Lee, Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy, AAPS J 17 (2015), pp. 535-545. L.R. Trevino, N. Shimasaki, W. Yang, J.C. Panetta, C. Cheng, D. Pei, D. Chan, A. Sparreboom, K.M. Giacomini, C.H. Pui, W.E. Evans and M.V. Relling, Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects, J Clin Oncol 27 (2009), pp. 5972- 5978. E. van de Steeg, V. Stranecky, H. Hartmannova, L. Noskova, M. Hrebicek, E. Wagenaar, A. van Esch, D.R. de Waart, R.P. Oude Elferink, K.E. Kenworthy, E. Sticova, M. al-Edreesi, A.S. Knisely, S. Kmoch, M. Jirsa and A.H. Schinkel, Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver, J Clin Invest 122 (2012), pp. 519-528. E. van de Steeg, C.M. van der Kruijssen, E. Wagenaar, J.E. Burggraaff, E. Mesman, K.E. Kenworthy and A.H. Schinkel, Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1), Drug Metab Dispos 37 (2009), pp. 277-281. E. van de Steeg, A. van Esch, E. Wagenaar, K.E. Kenworthy and A.H. Schinkel, Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice, Clin Cancer Res 19 (2013), pp. 821-832. E. van de Steeg, A. van Esch, E. Wagenaar, C.M. van der Kruijssen, O. van Tellingen, K.E. Kenworthy and A.H. Schinkel, High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel, Clin Cancer Res 17 (2011), pp. 294-301. E. van de Steeg, E. Wagenaar, C.M. van der Kruijssen, J.E. Burggraaff, D.R. de Waart, R.P. Elferink, K.E. Kenworthy and A.H. Schinkel, Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs, J Clin Invest 120 (2010), pp. 2942-2952. S. van Outryve, D. Schrijvers, J. van den Brande, P. Wilmes, J. Bogers, E. van Marck and J.B. Vermorken, Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review, Neth J Med 60 (2002), pp. 216-222. A. Vasilyeva, S. Durmus, L. Li, E. Wagenaar, S. Hu, A.A. Gibson, J.C. Panetta, S. Mani, A. Sparreboom, S.D. Baker and A.H. Schinkel, Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b, Cancer Res 75 (2015), pp. 2729-2736. T. Watanabe, H. Kusuhara, K. Maeda, Y. Shitara and Y. Sugiyama, Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans, J Pharmacol Exp Ther 328 (2009), pp. 652-662. T. Watanabe, H. Kusuhara and Y. Sugiyama, Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans, J Pharmacokinet Pharmacodyn 37 (2010), pp. 575-590. J.A. Wessels, T.W. Huizinga and H.J. Guchelaar, Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis, Rheumatology (Oxford) 47 (2008), pp. 249-255. P. Wu, T.E. Nielsen and M.H. Clausen, FDA-approved small-molecule kinase inhibitors, Trends Pharmacol Sci 36 (2015), pp. 422-439. X. Xiang, S.R. Jada, H.H. Li, L. Fan, L.S. Tham, C.I. Wong, S.C. Lee, R. Lim, Q.Y. Zhou, B.C. Goh, E.H. Tan and B. Chowbay, Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients, Pharmacogenet Genomics 16 (2006), pp. 683-691.